Relay Therapeutics, Inc. Common Stock

RLAYNASDAQUSD
19.91 USD
0.54 (2.79%)AT CLOSE (11:59 AM EDT)
19.90
0.02 (0.08%)
POST MARKET (AS OF 07:04 PM EDT)
Post Market
AS OF 07:04 PM EDT
19.90
0.02 (0.08%)
🔴Market: CLOSED

Relay Therapeutics, Inc. Common Stock (RLAY) trades at $19.91 per share. There is a divergence between signals — technical indicators rate "Strong Buy" but underlying fundamentals lean "Sell". Key drivers include a robust Altman Z-Score, a weak Piotroski F-Score of 1/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. Furthermore, RLAY is currently richly valued, trading at a premium to sector peers across key valuation metrics.

Technical & fundamental data as of Jul 17, 2026.

Open?$19.13
High?$20.29
Low?$18.85
Prev. Close?$19.37
Volume?2.2M
Avg. Volume?4.2M
VWAP?$19.95
Rel. Volume?0.51x
Bid / Ask
Bid?$16.95 × 100
Ask?$22.63 × 100
Spread?$5.68
Midpoint?$19.79
Valuation & Ratios
Market Cap?4.2B
Shares Out?191.6M
Float?116.7M
Float %?65.3%
P/E Ratio?N/A
P/B Ratio?6.57
EPS?-$1.25
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
Employees
192
Market Cap
4.2B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed
2020-07-16
Address
60 HAMPSHIRE STREET
CAMBRIDGE, MA 02139
Phone: 617-370-8837
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)? Bullish(+2/3)
Medium-Term (Wave)? Bullish(+1/3)
Short-Term (Ripple)? Bullish(+3/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
6
Z-Score?
100
Momentum?
25
Short Sent.?
11
Piotroski F-Score?1/9Weak
Altman Z-Score?39.62Safe
Confidence?55%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?36.88%Squeeze Risk
Short Interest?43.0M
Days to Cover?7.2
Free Float116.7M
Avg Daily Volume5.9M
Settlement Date2026-06-30
Financial Health
Current Ratio?22.13Strong
Quick Ratio?22.13Strong
Cash Ratio?6.88Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
58/100
P/E?
N/A
P/B?
Peers
100
S&P
28
6.57FAIR
P/S?
Peers
100
S&P
3
395.38HIGH
P/FCF?
N/A
EV/EBITDA?
S&P
97
-13.7CHEAP
EV/Sales?
Peers
100
S&P
3
376.22HIGH
Returns & Efficiency
ROE?
S&P
3
-42.5%WEAK
ROA?
S&P
3
-39.0%WEAK
Cash Flow & Enterprise
FCF?$-213383000
Enterprise Value?$4.0B
Fundamentals ratios updated end of day